An economic theory of the fourth hurdle

Health Economics (United Kingdom)

Volumn 22, Issue 5, 2013, Pages 600-610

  Rogowski, W H ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

fourth hurdle; healthcare coverage; healthcare reimbursement; new institutional economics; value of information

Indexed keywords

ARTICLE; BIOETHICS; CONCEPTUAL FRAMEWORK; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; LAW; POPULATION SIZE; PRIORITY JOURNAL; REIMBURSEMENT; THEORETICAL STUDY;

DECISION MAKING; HEALTH CARE RATIONING; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MODELS, ECONOMIC; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84875861247     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.2830     Document Type: Article

References (21)

1. Briggs A, Claxton K, Sculpher M,. 2006. Decision Modelling for Health Economic Evaluation. Oxford Univ. Press: Oxford.
2. Claxton K,. 1999. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics 18: 341-64. (Pubitemid 29242816)
3. Daniels N,. 2008. Just Health: Meeting Health Needs Fairly. Cambridge University Press: Cambridge.
4. Dixit AK,. 1996. The Making of Economic Policy: A Transaction-Cost Politics Perspective. MIT Press: Cambridge, Mass.
5. Fenwick E, Claxton K, Sculpher M,. 2008. The value of implementation and the value of information: combined and uneven development. Medical Decision Making 28: 21-32.
6. Fischer KE, Grosse SD, Rogowski WH,. 2011a. The role of HTA in coverage decisions on newborn screening. International Journal of Technology Assessment in Health Care 27: 313-21.
7. Fischer KE, Leidl R, Rogowski WH,. 2011b. A structured tool to analyse coverage decisions: development and feasibility test in the field of cancer screening and prevention. Health Policy 101: 290-9.
8. Gafni A, Birch S,. 2006. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Social Science & Medicine 62: 2091-100.
9. Hutton J, McGrath C, Frybourg JM, Tremblay M, Bramley-Harker E, Henshall C,. 2006. Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems). International Journal of Technology Assessment in Health Care 22: 10-8. (Pubitemid 43376234)
10. Kristensen FB, Chamova J, Hansen NW,. 2006. Toward a sustainable European Network for Health Technology Assessment. The EUnetHTA project. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 49: 283-5. (Pubitemid 43880419)
11. Lubbe W,. 2009. Post-utilitarianism and the prioritisation debate. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 103: 99-103.
12. Mossialos E, Mrazek M, Walley T,. 2004. Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality. Open Univ. Press: Maidenhead.
13. Payne K, Davies LM, Noyce PR, Weiss MC,. 2003. The value of the managed entry of new drugs: a case study of donepezil. International Journal of Technology Assessment in Health Care 19: 114-28. (Pubitemid 36356332)
14. Rawlins MD,. 2005. 5 NICE years. Lancet 365: 904-8. (Pubitemid 40332170)
15. Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N,. 2009a. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. Health Technology Assessment 13: 1-102.
16. Rogowski WH, Hartz SC, John JH,. 2008. Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine. BMC Health Services Research 8: 1-12.
17. Rogowski WH, Landauer M, John J,. 2009b. Entscheidungsanalytische Modellierung von Kosten pro QALY im Kontext des deutschen Sozialrechts. Gesundheitswesen 71: 739-50.
18. Schreyögg J, Stargardt T, Velasco-Garrido M, Busse R,. 2005. Defining the "health benefit basket" in nine European countries. Evidence from the European union health BASKET project. The European Journal of Health Economics 6 (Suppl 1): 2-10.
19. Taylor RS, Drummond MF, Salkeld G, Sullivan SD,. 2004. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329: 972-5. (Pubitemid 39422918)
20. Thurner PW, Kotzian P,. 2001. Comparative Health Care Systems. Outline for an empirical application of New Institutional Economics approaches. ECPR meeting. Grenoble.
21. Wailoo A, Anand P,. 2005. The nature of procedural preferences for health-care rationing decisions. Social Science & Medicine 60: 223-36. (Pubitemid 39452539)